Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

Drug tolerance is the basis for acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) including osimertinib, through mechanisms that still remain unclear. Here, we show that while AXL-low expressing EGFR mutated lung cancer (EGFRmut-LC) cells are more sensiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Rong, Yamada, Tadaaki, Kita, Kenji, Taniguchi, Hirokazu, Arai, Sachiko, Fukuda, Koji, Terashima, Minoru, Ishimura, Akihiko, Nishiyama, Akihiro, Tanimoto, Azusa, Takeuchi, Shinji, Ohtsubo, Koshiro, Yamashita, Kaname, Yamano, Tomoyoshi, Yoshimura, Akihiro, Takayama, Koichi, Kaira, Kyoichi, Taniguchi, Yoshihiko, Atagi, Shinji, Uehara, Hisanori, Hanayama, Rikinari, Matsumoto, Isao, Han, Xujun, Matsumoto, Kunio, Wang, Wei, Suzuki, Takeshi, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490421/
https://www.ncbi.nlm.nih.gov/pubmed/32929081
http://dx.doi.org/10.1038/s41467-020-18442-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490421/
https://www.ncbi.nlm.nih.gov/pubmed/32929081
http://dx.doi.org/10.1038/s41467-020-18442-4

Ejemplares similares